CIViC Evidence Items
4766 evidence items indexed
Evidence Level Distribution
CIViC evidence levels reflect study design quality, from A (strongest) to E (weakest).
AValidated — meta-analysis, systematic review, or major guideline
BClinical — prospective trial or retrospective cohort study
CCase study — single case report or small case series
DPreclinical — in vitro or animal model data
EInferential — computational prediction or biological rationale
Gene × Evidence Type
Count of CIViC evidence items per gene and evidence type category. Hover a column header for the type definition.
| Predictive | Diagnostic | Prognostic | Functional | Predispos. | Oncogenic | |
|---|---|---|---|---|---|---|
| BCR::ABL1 | 323 | 11 | ||||
| BRAF | 186 | 4 | 26 | 2 | 1 | |
| EGFR | 248 | 12 | 3 | 2 | ||
| EML4::ALK | 64 | |||||
| ERBB2 | 142 | 2 | ||||
| FLT3 | 55 | 2 | 21 | |||
| KIT | 102 | 3 | 7 | |||
| KRAS | 159 | 4 | 24 | 4 | ||
| PIK3CA | 156 | 16 | 4 | |||
| PTEN | 53 | 1 | 3 | 1 | 2 | 1 |
| TP53 | 52 | 40 | 100 | 2 | ||
| VHL | 5 | 2 | 3 | 635 | 15 |
Predictive:Links a variant to treatment response or resistance
Diagnostic:Supports or refutes a specific disease diagnosis
Prognostic:Informs disease progression or clinical outcome
Functional:Characterises the biological effect of a variant
Predisposing:Germline variant associated with cancer predisposition
Oncogenic:Characterises the variant's role in oncogenesis
| Level | Gene | Variant | Type | Direction | Significance | Disease | Drugs | Source |
|---|---|---|---|---|---|---|---|---|
| B | NPM1 | MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia With Mutated NPM1 | Döhner et al., 2005 | |
| B | FGFR1 | Amplification | Predictive | Supports | Sensitivity/Response | Breast Cancer | Everolimus,Endocrine Drug Therapy | Drago et al., 2019 |
| C | SRF::v | Fusion | Diagnostic | Supports | Positive | Myofibroma And Myopericytoma | Papa et al., 2023 | |
| C | SRF::v | Fusion | Diagnostic | Supports | Positive | Myofibroma And Myopericytoma | Yin et al., 2024 | |
| A | PIK3CA | H1047R OR PIK3CA H1047Y OR PIK3CA H1047L OR PIK3CA H1047D OR PIK3CA H1047I OR PIK3CA H1047N OR PIK3CA H1047P OR PIK3CA H1047Q OR PIK3CA H1047T | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fulvestrant,Inavolisib,Palbociclib | Wedam et al., 2025 |
| A | PIK3CA | E545K OR PIK3CA E545Q OR PIK3CA E545A OR PIK3CA E545G OR PIK3CA E545V OR PIK3CA E545D OR PIK3CA E545L OR PIK3CA E545R | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fulvestrant,Palbociclib,Inavolisib | Wedam et al., 2025 |
| A | PIK3CA | E542K OR PIK3CA E542Q OR PIK3CA E542A OR PIK3CA E542D OR PIK3CA E542G OR PIK3CA E542R OR PIK3CA E542V | Predictive | Supports | Sensitivity/Response | Breast Cancer | Inavolisib,Fulvestrant,Palbociclib | Wedam et al., 2025 |
| A | PIK3CA | Q546K OR PIK3CA Q546E OR PIK3CA Q546P OR PIK3CA Q546R OR PIK3CA Q546L OR PIK3CA K111E OR PIK3CA K111N OR PIK3CA K111R OR PIK3CA Q546H | Predictive | Supports | Sensitivity/Response | Breast Cancer | Inavolisib,Fulvestrant,Palbociclib | Wedam et al., 2025 |
| A | PIK3CA | G1049S OR PIK3CA G1049R OR PIK3CA G106V OR PIK3CA G106R OR PIK3CA G1049A OR PIK3CA G106S OR PIK3CA G106A OR PIK3CA G106D OR PIK3CA G118D OR PIK3CA G1049C OR PIK3CA G1049D | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fulvestrant,Inavolisib,Palbociclib | Wedam et al., 2025 |
| A | PIK3CA | N345K OR PIK3CA N345D OR PIK3CA N345H OR PIK3CA N345I OR PIK3CA N345S OR PIK3CA N345T OR PIK3CA N345Y | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fulvestrant,Palbociclib,Inavolisib | Wedam et al., 2025 |
| A | PIK3CA | R88Q OR PIK3CA C420R OR PIK3CA M1043V OR PIK3CA M1043I OR PIK3CA M1043T | Predictive | Supports | Sensitivity/Response | Breast Cancer | Fulvestrant,Inavolisib,Palbociclib | Wedam et al., 2025 |
| A | PIK3CA | E453K OR PIK3CA E453Q OR PIK3CA E453A OR PIK3CA E453D OR PIK3CA E453G OR PIK3CA E453V | Predictive | Supports | Sensitivity/Response | Breast Cancer | Inavolisib,Fulvestrant,Palbociclib | Wedam et al., 2025 |
| C | FGFR1 | Amplification | Predictive | Does Not Support | Sensitivity/Response | Breast Cancer | Pemigatinib | Rodón et al., 2024 |
| B | CDKN2A | Loss | Predictive | Supports | Resistance | Bladder Urothelial Carcinoma | Immune Checkpoint Inhibitor | Adib et al., 2021 |
| D | FGFR1 | Amplification | Predictive | Supports | Sensitivity/Response | Breast Cancer | Futibatinib | Sootome et al., 2020 |
| B | BCOR::CCNB3 | Fusion | Diagnostic | Supports | Positive | Sarcoma With BCOR Genetic Alterations | Ludwig et al., 2017 | |
| B | CTAG1B | Expression | Predictive | Supports | Sensitivity/Response | Myxoid Liposarcoma | Letetresgene Autoleucel | D'Angelo et al., 2025 |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Ipilimumab/Nivolumab Regimen | Ready et al., 2019 |
| C | EWSR1::NFATC2 | Fusion | Diagnostic | Supports | Positive | Round Cell Sarcoma With EWSR1-non-ETS Fusion | Wang et al., 2019 | |
| C | EWSR1::NFATC2 | Fusion | Diagnostic | Supports | Positive | Round Cell Sarcoma With EWSR1-non-ETS Fusion | Szuhai et al., 2009 | |
| D | MMP1 | Overexpression | Predictive | Supports | Resistance | Estrogen-receptor Positive Breast Cancer | Sacituzumab Govitecan | Chen et al., 2025 |
| B | PIK3CA | Exon 21 Mutation AND PIK3CA Exon 10 Mutation | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Aspirin | Martling et al., 2025 |
| B | LRP1B | Loss-of-function | Predictive | Supports | Sensitivity/Response | Lung Adenocarcinoma | Immune Checkpoint Inhibitor | He et al., 2023 |
| B | v::TFE3 | Fusion | Diagnostic | Supports | Positive | Perivascular Epithelioid Cell Tumor | Schoolmeester et al., 2015 | |
| B | v::TFE3 | Fusion | Diagnostic | Supports | Positive | Perivascular Epithelioid Cell Tumor | Papke et al., 2025 | |
| C | FUS::NFATC2 | Fusion | Diagnostic | Supports | Positive | Round Cell Sarcoma With EWSR1-non-ETS Fusion | Brohl et al., 2014 | |
| D | RET | M918T | Oncogenic | Supports | Oncogenicity | Cancer | Ceccherini et al., 1997 | |
| B | v::NCOA2 | Fusion | Diagnostic | Supports | Positive | Spindle Cell Rhabdomyosarcoma | Whittle et al., 2022 | |
| C | v::NCOA2 | Fusion | Diagnostic | Supports | Positive | Spindle Cell Rhabdomyosarcoma | Mosquera et al., 2013 | |
| C | EWSR1::PATZ1 | Fusion | Diagnostic | Supports | Positive | Round Cell Sarcoma With EWSR1-non-ETS Fusion | Bridge et al., 2019 | |
| C | EWSR1::PATZ1 | Fusion | Diagnostic | Supports | Positive | Round Cell Sarcoma With EWSR1-non-ETS Fusion | Michal et al., 2021 | |
| C | EWSR1::PATZ1 | Fusion | Diagnostic | Supports | Positive | Round Cell Sarcoma With EWSR1-non-ETS Fusion | Dehner et al., 2024 | |
| B | TMB | High | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Durvalumab/Tremelimumab Regimen | Rizvi et al., 2020 |
| D | CCNE1 | Amplification | Predictive | Supports | Sensitivity/Response | Ovarian Carcinoma | Camonsertib,Lunresertib | Xu et al., 2025 |
| D | CCNE1 | Amplification | Predictive | Supports | Sensitivity/Response | Endometrial Carcinoma | Camonsertib,Lunresertib | Xu et al., 2025 |
| B | RET | M918T | Oncogenic | Supports | Oncogenicity | Medullary Thyroid Carcinoma | Elisei et al., 2008 | |
| C | ARAF | S214C | Predictive | Supports | Sensitivity/Response | Lung Non-small Cell Carcinoma | Sorafenib | Imielinski et al., 2014 |
| C | NRAS | G13D | Predictive | Supports | Sensitivity/Response | Melanoma | Tanespimycin | Banerji et al., 2008 |
| C | NRAS | Q61L | Predictive | Supports | Sensitivity/Response | Melanoma | Temozolomide | Soon et al., 2011 |
| C | NRAS | Q61R | Predictive | Supports | Sensitivity/Response | Melanoma | Temozolomide | Soon et al., 2011 |
| B | NRAS | Q61 | Predictive | Supports | Resistance | Colorectal Cancer | Cetuximab,Chemotherapy | De Roock et al., 2010 |
| D | ALK | R1275Q | Predictive | Supports | Sensitivity/Response | Cancer | ALK Inhibitor TAE684 | George et al., 2008 |
| B | RET | M918T | Prognostic | Supports | Poor Outcome | Medullary Thyroid Carcinoma | Egawa et al., 1998 | |
| B | BRAF | V600E | Prognostic | Does Not Support | Poor Outcome | Melanoma | Meckbach et al., 2014 | |
| C | KRAS | G12D | Predictive | Supports | Resistance | Lung Adenocarcinoma | Dabrafenib | Rudin et al., 2013 |
| D | BRAF | V600E | Predictive | Supports | Sensitivity/Response | Colorectal Cancer | Vemurafenib | Yang et al., 2012 |
| B | NPM1 | W288FS | Prognostic | Does Not Support | Better Outcome | Acute Myeloid Leukemia | Ley et al., 2010 | |
| B | DNMT3A | R882 | Prognostic | Does Not Support | Better Outcome | Acute Myeloid Leukemia | Ley et al., 2010 | |
| B | NPM1 | EXON 11 MUTATION | Diagnostic | Supports | Positive | Acute Myeloid Leukemia | Gale et al., 2008 | |
| B | NPM1 | EXON 11 MUTATION | Predictive | Supports | Sensitivity/Response | Acute Myeloid Leukemia | Tretinoin | Schlenk et al., 2009 |